Analysis of data from women diagnosed with stage I to IIIA BC at Kaiser Permanente Northern California and Washington databases reported an increasing trend in NACT use across BC subtypes, overall, and specifically among those with HER2-positive tumors19. This evidence concerns the gene ERBB2 and breast cancer.